| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
HYDERABAD, India—Dr. Reddy's Laboratories Ltd.announced Oct. 22 that is has reached conditional agreement with Leiden, theNetherlands-based OctoPlus on a public offer for all issued and outstandingordinary shares in the capital of OctoPlus at an offer price totaling roughly$36 million.
 
 
This price represents a premium of 30 percent overOctoPlus' most recent closing price at the time of the announcement and apremium of 36 percent, 28 percent and 14 percent, respectively, over OctoPlus'average closing price for the past three, six and 12 months.
 
 
The executive board and the supervisory board ofOctoPlus are said to both fully support the offer, and are recommending thatOctoPlus' shareholders sell their stock to Dr. Reddy's.
 
 
G.V. Prasad, CEO of Dr. Reddy's, says his companylooks forward to having a research and development base in the Leiden area andadds, "the acquisition gives us the ability to strengthen our technologicalcapabilities in the areas of drug delivery."
 
 
With the recent "value erosion" of Locteron, ahepatitis C drug OctoPlus was co-developing with Pittsboro, N.C.-based BiolexTherapeutics—but which never gained financing to push is to Phase III clinicaltesting status—OctoPlus' leaders felt that they needed to review a number ofalternative strategies for our company, finally concluding, according toOctoPlus, that the intended offer by Dr. Reddy's best serves the interest of thecompany's key stakeholders, "including our employees and shareholders."
 
 
Dr. Reddy's maintains that OctoPlus' developmentand manufacturing platform perfectly fits with its own marketing abilities,with a news release about the deal noting that "Dr. Reddy's is keen to furtherexpand into the fast growing fee-for-service business" and, to that extent, Dr.Reddy's "will retain OctoPlus as a specialist standalone entity to developspecialty generics for Dr. Reddy's. OctoPlus will become Dr. Reddy's center ofexcellence for complex injectables with retention of our highly skilled anddedicated professionals in our Leiden facility."
  
 
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue